Strategies involving dual inhibition of ALK and other pathways, including MYC, Src, JNK/c-Jun, and Wnt/β-catenin, have demonstrated potential in overcoming resistance and hindering tumor growth in ALK+ cancers. Here, ALK is linked to cancer.